Category: Articles

Biosimilars: Getting the flock to market – PMLiVE – PMLiVE

[ad_1] Biosimilars have now been with us for over 10 years. In case you haven’t been paying attention for the past decade, a biosimilar is a highly similar version of an originator biologic agent, offering comparable efficacy and safety but with a lower acquisition cost.   Biosimilars don’t offer the…

Biocon backs away from biosimilar filings in Europe – PMLiVE

[ad_1] Indian biotech Biocon has said its plan to launch two new biosimilars in Europe has been stymied by issues at its manufacturing facility. In a statement, the company said it had been forced to withdraw its regulatory filings for biosimilar versions of Roche’s breast cancer drug Herceptin (trastuzumab) and…

Remicade Is a Litmus Test for PBMs – Bloomberg

[ad_1] Biosimilars — the equivalent of generic drugs for complicated and expensive medicines made by living cells — are supposed to reduce prices and save the health care system billions of dollars by finally bringing competition to blockbuster drugs. But as Bloomberg News has chronicled, they’ve been slow to gain traction.   Groundwork…

Supreme Court Ruling on Biosimilars Will Lower Drug Costs – Medscape

[ad_1] MADRID — A unanimous Supreme Court decision on biosimilars, which industry insiders anticipate will lower drug costs, probably won’t lead to cheaper prices for patients or physicians wrangling with nonmedical switching, delegates heard at the recent European League Against Rheumatism (EULAR) Congress 2017. The European Congress kicked off in…